Novartis to Acquire Avidity Biosciences for $12 Billion to Boost Rare-Disease Portfolio
Novartis announced a $12 billion all-cash acquisition of Avidity Biosciences, gaining access to RNA-based therapies for rare muscle disorders. The move aligns with the company’s broader push into gene and precision-medicine platforms as it faces upcoming patent expirations on key blockbuster drugs.